YKL-40-TARGETING HUMAN MONOCLONAL ANTIBODY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 27, 2022
app pub date -
Sep 7, 2020
filing date -
Sep 7, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to a monoclonal antibody binding specifically to YKL-40. A high expression level of YKL-40 is associated with the proliferation and metastasis of cancer and a monoclonal antibody against YKL-40 exhibits an effect of inhibiting the proliferation and metastasis of cancer. Thus, the monoclonal antibody of the present disclosure can be advantageously used for diagnosing, preventing or treating cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully